SVRA logo

SVRA
Savara Inc

22,690
Mkt Cap
$1.08B
Volume
1.99M
52W High
$7.01
52W Low
$1.89
PE Ratio
-9.90
SVRA Fundamentals
Price
$5.28
Prev Close
$5.16
Open
$5.33
50D MA
$6.00
Beta
1.08
Avg. Volume
1.45M
EPS (Annual)
-$0.4838
P/B
9.71
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the company, MarketBeat reports. One...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Savara (NASDAQ:SVRA) Trading 2.5% Higher - Should You Buy?
Savara (NASDAQ:SVRA) Shares Up 2.5% - Still a Buy...
MarketBeat·5d ago
News Placeholder
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with...
Business Wire·12d ago
News Placeholder
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On January 15, 2026...
Business Wire·23d ago
News Placeholder
Savara Inc. (NASDAQ:SVRA) Given Average Rating of "Moderate Buy" by Analysts
Savara Inc. (NASDAQ:SVRA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten analysts that are covering the company, MarketBeat Ratings reports. One equities research...
MarketBeat·28d ago
News Placeholder
PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
PANTHERx Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical...
Business Wire·1mo ago
News Placeholder
Savara (NASDAQ:SVRA) Shares Down 5.1% - Should You Sell?
Savara (NASDAQ:SVRA) Trading Down 5.1% - What's Next...
MarketBeat·1mo ago
News Placeholder
Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December
Savara Inc. (NASDAQ:SVRA - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 20,185,493 shares, an increase of 33.1% from the...
MarketBeat·1mo ago
News Placeholder
Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA
Swedbank AB acquired a new stake in Savara Inc. (NASDAQ:SVRA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor...
MarketBeat·1mo ago
News Placeholder
What is HC Wainwright's Forecast for Savara FY2027 Earnings?
Savara Inc. (NASDAQ:SVRA - Free Report) - Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Savara in a research note issued on Tuesday...
MarketBeat·2mo ago
<
1
2
...
>

Latest SVRA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.